Trial
NCT03881735
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
Celgene
Condition
Blasts Under 5 Percent of Peripheral Blood White Cells
Intervention
Enasidenib
Why stopped
no accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-10